Optimization of Expression and Purification of an Anti-Inflammatory Binding Motif
This study outlines the development of a protocol for producing codon-optimized Gevokizumab scFv to hinder IL-1β activation, with findings that suggest enhanced protein expression in optimized constructs, which paves the way for potential therapeutic applications in inflammatory diseases.
Posted by buchanle on Wednesday, June 25th, 2025 in May 2025, Gevokizumab, Inflammatory, Osteoarthritis, Protein Expression, scFv